Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
about
Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast CancerEnzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
P2860
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Number needed to treat and ass ...... ion-resistant prostate cancer.
@en
Number needed to treat and ass ...... ion-resistant prostate cancer.
@nl
type
label
Number needed to treat and ass ...... ion-resistant prostate cancer.
@en
Number needed to treat and ass ...... ion-resistant prostate cancer.
@nl
prefLabel
Number needed to treat and ass ...... ion-resistant prostate cancer.
@en
Number needed to treat and ass ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P1476
Number needed to treat and ass ...... ion-resistant prostate cancer.
@en
P2093
Arie Barlev
Bhavik J Pandya
Bruce Brown
Hongbo Yang
Marjan Massoudi
Scott Flanders
P2860
P304
P356
10.1080/13696998.2016.1229670
P407
P50
P577
2016-08-29T00:00:00Z